Detail akcie Amgen Inc online

Business Summary: Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Amgen Inc revenues increased 19% to $33.42B. Net income decreased 39% to $4.09B. Revenues reflect TEPEZZA segment increase from $448M to $1.85B, KRYSTEXXA segment increase from $272M to $1.19B, US segment increase of 21% to $23.3B, ROW segment increase of 14% to $8.73B. Net income was offset by Other income, net - Balancing value decrease of 82% to $437M (income), Selling.